Analysis of Risk Factors and Outcome for Extramedullary Relapses Post Allogeneic Stem Cell Transplantation for Myeloma.
Authors: Htut Myo , Sahebi Firoozeh , Somlo George , Parker Pablo , Karanes Chatchada , Dagis Andy , Hmwe Susan , Paris Tanya , Murata-Collins Joyce , Popplewell Leslie , Palmer Joycelynne , Forman Stephen , Krishnan Amrita 
Published: October 2019

Abstract 4562

Analysis of Risk Factors and Outcome for Extramedullary Relapses post Allogeneic Stem Cell Transplantation for Myeloma

Relapse after both autologous and allogeneic hematopietic stem cell transplant (HSCT) is common in multiple myeloma (MM). Unusual sites of relapse have been reported after allogeneic HSCT in the form of isolated extramedullary (EM) lesion or light chain escape. It is hypothesized that these EM relapses are due to changes in the marrow microenvironment or selection of resistant subclones from therapy with novel agents and or allogeneic stem cell transplantation. Several case reports have shown that EM relapse is associated with dismal prognosis compared to medullary or bone marrow (BM) relapse. To study the relapse patterns and outcome, we performed a retrospective analysis of 56 pts who underwent tandem autologous-nonmyeloablative allogeneic HSCT (auto-allo) or reduced intensity conditioning (RIC) allogeneic transplant.

Between January, 2000 to March 2008, 38 pts received planned auto-allo HSCT using melphalan (200 mg/m2) prior to auto-HSCT and TBI (200 cGy) prior to allo-HSCT and 18 pts received RIC allo-HSCT following fludarabine (125mg/m2) and melphalan 140mg/m2. Donors included 52 HLA matched siblings and 4 matched unrelated donors.Table 1.Patients characteristicsParametersPts without relapse (n)BM relapse (n)EM relapse (n)P-valueTotal number of patients33167.Age at transplant (median, yr.)50.85154.10.84Interval between diagnosis-transplant (median, mo.)11.79.414.60.12B2-micr (median)2.06 (1.18-10)1.67 (1.28-2.15)2.08 (0.79- 9.05)0.15Median f/u for alive pts (yr.)6.88.79.6.Type of transplant....Auto- allo graft70% (23)69 % (11)57 % (4)0.84RIC30% (10)31% (5)43% (3)Response before allograft....CR/PR64% (21)56% (9)71% (5)0.79MR/SD/RE/refractory36% (12)44% (7)29% (2)Stage III disease at the time of transplant78% (25)81% (13)100% (7)0.94Ch 13 del at dx18% (6)12% (2)29% (2)0.69Novel agent prior to transplant45% (15)38% (6)57% (4)0.74

RESULTS

After a median follow up of 7.8 years; there were 16 BM and 7 EM relapses. There was no correlation between either relapse or the pattern of relapse (BM and EM) and development of acute and chronic graft vs. chronic disease (GVHD). The risk ratio for BM relapse in 5 year is 0.27 for patients with chronic GVHD (cGVHD) and 0.15 for patients without cGVHD (P=0.69). The risk ratio for EM relapse in 5 year is 0.12 for patients with cGVHD and 0.25 for patients without cGVHD (P=0.10) (Figure 1).

Overall survival (OS) and progression-free survival (PFS) for the whole group (N=56) is shown in figure 1. Four year OS was 43% in EM group and 88% in BM group (P=0.005) (Figure 3).

There were no significant differences between age, B2 microglobulin, numbers of treatment before HSCT, use of novel agents before HSCT, cytogenetics, stage, transplant regimen and development of GVHD and pattern of relapse (BM vs. EM). In conclusion our data suggest that EM relapse can occur post allogeneic HSCT and is associated with shorter overall survival. The development of GVHD does not prevent against EM relapse.

Disclosures:

No relevant conflicts of interest to declare.